Zymeworks (ZYME) Cash from Investing Activities (2021 - 2026)
Zymeworks' (ZYME) quarterly Cash from Investing Activities came in at $70.0 million in Q1 2026, up 474.28% year-on-year from $12.2 million in Q1 2025, and up 1203.26% quarter-over-quarter from $5.4 million in Q4 2025.
Zymeworks (ZYME) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Zymeworks has disclosed Cash from Investing Activities across 6 years of filings, most recently posting $70.0 million for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $70.0 million, up 474.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.4 million (up 44.95% YoY), and the FY2025 annual result was $26.7 million, down 31.2% from the prior year.
- Cash from Investing Activities came in at $70.0 million for Q1 2026 at Zymeworks, up from $5.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $72.3 million in Q3 2024 to a low of -$138.2 million in Q1 2023.
- The 5-year median for Cash from Investing Activities is -$6.2 million (2024), against an average of -$7.4 million.
- Across the five-year window, Cash from Investing Activities tumbled 1088.21% in 2022 and soared 1129.3% in 2024, its largest moves.
- Zymeworks' Cash from Investing Activities stood at -$22.1 million in 2022, then soared by 93.94% to -$1.3 million in 2023, then slumped by 364.77% to -$6.2 million in 2024, then surged by 186.39% to $5.4 million in 2025, then jumped by 1203.26% to $70.0 million in 2026.
- The last three Cash from Investing Activities figures came in at $70.0 million (Q1 2026), $5.4 million (Q4 2025), and $368000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | 69.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.96 Mn |
| Mar 31, 2026 | 69.96 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Sep 30, 2025 | 368,000.00 |
| Sep 30, 2025 | 368,000.00 |
| Jun 30, 2025 | 8.75 Mn |
| Jun 30, 2025 | 8.75 Mn |
| Mar 31, 2025 | 12.18 Mn |
| Mar 31, 2025 | 12.18 Mn |
| Dec 31, 2024 | -6.21 Mn |
| Dec 31, 2024 | -6.21 Mn |
| Sep 30, 2024 | 72.26 Mn |
| Sep 30, 2024 | 72.26 Mn |
| Jun 30, 2024 | -19.97 Mn |
| Jun 30, 2024 | -19.97 Mn |
| Mar 31, 2024 | -7.32 Mn |
| Mar 31, 2024 | -7.32 Mn |
| Dec 31, 2023 | -1.34 Mn |
| Dec 31, 2023 | -1.34 Mn |